Standardization and advancements efforts in breast diffusion-weighted imaging.

Recent advancements in breast magnetic resonance imaging (MRI) have significantly enhanced breast cancer detection and characterization. Breast MRI offers superior sensitivity, particularly valuable for high-risk screening and assessing disease extent. Abbreviated protocols have emerged, providing efficient cancer detection while reducing scan time and cost. Diffusion-weighted imaging (DWI), a non-contrast technique, has shown promise in differentiating malignant from benign lesions. It offers shorter scanning times and eliminates contrast agent risks. Apparent diffusion coefficient (ADC) values provide quantitative measures for lesion characterization, potentially reducing unnecessary biopsies. Studies have revealed some correlations between ADC values and hormone receptor status in breast cancers, although substantial variability exists among studies. However, standardization remains challenging. Initiatives such as European Society of Breast Imaging (EUSOBI), Diffusion-Weighted Imaging Screening Trial (DWIST), Quantitative Imaging Biomarkers Alliance (QIBA) have proposed guidelines to ensure consistency in imaging protocols and equipment specifications, addressing variability in ADC measurements across different sites and vendors. Advanced techniques like Intravoxel incoherent motion (IVIM) and non-Gaussian DWI offer insights into tissue microvasculature and microstructure. Despite ongoing challenges, the integration of these advanced MRI techniques shows great promise for improving breast cancer diagnosis, characterization, and treatment planning. Continued research and standardization efforts are crucial for maximizing the potential of breast DWI in enhancing patient care and outcomes.